Gland Pharma Q3 Results: Net Profit Increases 7% to Rs 205 Crore
Gland Pharma has reported a 7% year-on-year (YoY) increase in net profit for the third quarter of the financial year 2025, reaching Rs 205 crore. This marks an improvement from the Rs 192 crore profit recorded in the same quarter of the previous year.
Revenue and Financial Performance
- Revenue from operations: Declined by 10% YoY to Rs 1,384 crore in Q3FY25.
- EBITDA (Earnings Before Interest, Taxes, Depreciation, and Amortization): Increased 1% YoY to Rs 360 crore.
- EBITDA margin: Expanded by 300 basis points to 26%, reflecting improved cost efficiencies.
Research & Development and Regulatory Approvals
- R&D expenses: Stood at Rs 43.7 crore, accounting for 4.3% of revenue in Q3FY25.
- Regulatory approvals: The company filed 4 abbreviated new drug applications (ANDAs) and received 8 ANDA approvals in the US during the quarter.
Capital Expenditure and Facility Inspections
- Total capital expenditure: Rs 138 crore incurred during Q3FY25.
- USFDA inspections: The company received Establishment Inspection Reports (EIRs) confirming the successful closure of inspections at its Dundigal and Pashamylaram facilities in Hyderabad.
Complex Injectables and Future Prospects
Gland Pharma continues to expand its complex injectables portfolio, having completed nine filings from its targeted 19-product portfolio. Currently, six complex products are already launched, with three more pending approval. These products address an IQVIA market opportunity of $7.1 billion, signaling significant growth potential.
Additionally, the company is co-developing 15 complex formulations in partnership with MAIA Pharmaceuticals Inc. This includes seven 505(b)(2) applications and eight ANDAs at various stages of development, with commercialization expected to begin in FY27.
Biologics Expansion and Future Revenue Growth
The company is leveraging its biologics manufacturing facility at Genome Valley, Hyderabad, in collaboration with a leading pharmaceutical firm. This partnership is expected to enhance Gland Pharma's presence in the biologics contract development and manufacturing organization (CDMO) segment, generating additional revenue starting next financial year.
Disclaimer: The views and investment tips expressed in this article are for informational purposes only and do not represent financial advice. The views expressed are those of the sources cited and not necessarily those of this website or its management. Investing in equities or other financial instruments carries the risk of financial loss. Readers must exercise due caution and conduct their own research before making any investment decisions. We are not liable for any losses incurred as a result of decisions made based on this article. Please consult a qualified financial advisor before making any investment.
0 comments:
Post a Comment